GLP-1 Medicines May Help People with Bipolar Disorder

Topic: Health

Researchers from Griffith University found that people taking semaglutide (Ozempic or Wegovy) had lower rates of psychiatric hospitalization. This suggests that GLP-1 medicines may have benefits beyond treating diabetes and obesity.

GLP-1 receptor agonists are widely used to treat diabetes and support weight loss. But new research from Griffith University shows they may also help people with bipolar disorder.

Bipolar disorder is a serious mental health condition that affects about 37 million people worldwide. It often occurs together with diabetes and obesity, which may share some underlying biological mechanisms. Researchers led by Professor Mark Taylor analyzed nationwide Swedish data from nearly 15,000 people with bipolar disorder who had been prescribed GLP-1 medicines over a 15-year period.

The study found that semaglutide use was associated with a 21 percent lower risk of psychiatric hospitalization compared to periods when they were not taking GLP-1 medicines. This suggests that semaglutide may help protect the brain by reducing inflammation, cellular stress, and other biological processes associated with bipolar disorder.

However, the same pattern was not seen with every GLP-1 medication. Liraglutide and dulaglutide were not associated with a reduced risk of psychiatric hospitalization. Professor Taylor hopes that these findings will now be examined in a randomized controlled trial to provide stronger evidence about whether semaglutide can improve psychiatric outcomes in people with bipolar disorder.

Why It Matters

This research is important because it suggests that GLP-1 medicines may have benefits beyond treating diabetes and obesity. This could lead to new treatments for people with bipolar disorder, which affects millions of people worldwide.

Key Facts

• 37 million people worldwide live with bipolar disorder.
• Semaglutide use was associated with a 21 percent lower risk of psychiatric hospitalization.
• The study analyzed nationwide Swedish data from nearly 15,000 people with bipolar disorder who had been prescribed GLP-1 medicines over a 15-year period.
• Liraglutide and dulaglutide were not associated with a reduced risk of psychiatric hospitalization.
• Professor Mark Taylor hopes that these findings will now be examined in a randomized controlled trial.

Key Terms

GLP-1 receptor agonists

Medicines that mimic the action of a natural hormone to help treat diabetes and obesity.

Implications

This research is important because it suggests that GLP-1 medicines may have benefits beyond treating diabetes and obesity. This could lead to new treatments for people with bipolar disorder, which affects millions of people worldwide.